Drug Profile
Research programme: macrophage migration inhibitory factor inhibitors - Carolus Therapeutics
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Carolus Therapeutics
- Class Monoclonal antibodies; Peptides; Small molecules
- Mechanism of Action Macrophage migration inhibitory factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Inflammation; Transplant rejection
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 16 Jul 2016 No recent reports of development identified for research development in Inflammation in USA
- 16 Jul 2016 No recent reports of development identified for research development in Transplant-rejection in USA